Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of PF-05280586 versus rituximab for first-line treatment of low tumor burden follicular lymphoma
2014-000132-41Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in follicular lymphoma (FL) and B-cell non-Hodgkin lymphoma (B-NHL) (2 arms), sponsored by Pfizer. Primary endpoint: Overall Response Rate at Week 26. Started Jun 2014; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on 2014-000132-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000132-41.